A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone

British Journal of Dermatology

Volumn 172, Issue 3, 2015, Pages 760-768

  Hall, R P ^a   Fairley, J ^b   Woodley, D ^c   Werth, V P ^d   Hannah, D ^a   Streilein, R D ^a   McKillip, J ^b   Okawa, J ^d   Rose, M ^d   Keyes Elstein, L L ^e   Pinckney, A ^e   Overington, A ^e   Wedgwood, J ^f   Ding, L ^f   Welch, B ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e RHO INC   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; PLACEBO; PREDNISONE; DERMATOLOGICAL AGENT; DESMOGLEIN 1; DESMOGLEIN 3; IMMUNOGLOBULIN G;

ADD ON THERAPY; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PEMPHIGUS VULGARIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PEMPHIGUS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; DERMATOLOGIC AGENTS; DESMOGLEIN 1; DESMOGLEIN 3; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLIXIMAB; MALE; MIDDLE AGED; PEMPHIGUS; PREDNISONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925297211     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13350     Document Type: Article

References (22)

1. Risser J, Lewis K, Weinstock MA,. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 2009; 145: 1005-8.
2. Langan SM, Smeeth L, Hubbard R, et al,. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
3. Martin LK, Werth VP, Villaneuva EV, et al,. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. JAAD 2011; 64: 903-8.
4. Pardo J, Mercader P, Mahiques L, et al,. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153: 222-3.
5. Jacobi A, Schuler G, Hertl M,. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153: 448-9.
6. Berookhim B, Fischer HD, Weinberg JM,. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004; 74: 245-7.
7. Lin MH, Hsu CK, Lee JY,. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005; 141: 680-2.
8. Feliciani C, Toto P, Amerio P, et al,. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000; 114: 71-7.
9. Ameglio F, D'Auria L, Cordiali-Fei P, et al,. Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients' age. J Biol Regul Homeost Agents 1999; 13: 220-4.
10. Feliciani C, Toto P, Wang B, et al,. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol 2003; 12: 466-71.
11. Amagai M, Ikeda S, Shimizu H, et al,. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. JAAD 2009; 60: 595-603.
12. Beissert S, Mimouni D, Kanwar AJ, et al,. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130: 2041-8.
13. Basra MK, Fenech R, Gatt RM, et al,. The Dermatology Life Quality Index 1994 2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
14. Rosenbach M, Murrell D, Bystryn JC, et al,. Comparison of reliability and validity between two outcome instruments for pemphigus. J Invest Dermatol 2009; 129: 2404-10.
15. Levesque MC, Moody MA, Hwang KK, et al,. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009; 6: e1000107.
16. Salmon-Ceron D, Tubach F, Lortholary O, et al,. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70: 616-23.
17. Atteno M, Peluso R, Costa L, et al,. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 2010; 29: 399-403.
18. Delabaye I, De Keyser F,; the REMITRACT study group. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther 2010; 12: R121.
19. Reinisch W, Sandborn WJ, Rutgeerts P, et al,. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18: 201-11.
20. Mouquet H, Musette P, Gougeon ML, et al,. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008; 128: 2859-69.
21. Joly P, Mouquet H, Roujeau JC, et al,. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52.
22. Anolik JH, Ravikumar R, Barnard J, et al,. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008; 180: 688-92.